[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE69940692D1 - Verwendung von immunogenen immunsuppressiven und/oder angiogenen proteinen die inaktiviert sind, verfahren zur deren herstellung, und verwendungen als pharmazeutikum oder impfstoff - Google Patents

Verwendung von immunogenen immunsuppressiven und/oder angiogenen proteinen die inaktiviert sind, verfahren zur deren herstellung, und verwendungen als pharmazeutikum oder impfstoff

Info

Publication number
DE69940692D1
DE69940692D1 DE69940692T DE69940692T DE69940692D1 DE 69940692 D1 DE69940692 D1 DE 69940692D1 DE 69940692 T DE69940692 T DE 69940692T DE 69940692 T DE69940692 T DE 69940692T DE 69940692 D1 DE69940692 D1 DE 69940692D1
Authority
DE
Germany
Prior art keywords
immunosuppressive
immunogenic
inactived
vaccines
pharmaceuticals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69940692T
Other languages
English (en)
Inventor
Jean-Francois Zagury
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neovacs SA
Original Assignee
Neovacs SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neovacs SA filed Critical Neovacs SA
Application granted granted Critical
Publication of DE69940692D1 publication Critical patent/DE69940692D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1072—Regulatory proteins, e.g. tat, rev, vpt
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DE69940692T 1998-07-15 1999-06-15 Verwendung von immunogenen immunsuppressiven und/oder angiogenen proteinen die inaktiviert sind, verfahren zur deren herstellung, und verwendungen als pharmazeutikum oder impfstoff Expired - Lifetime DE69940692D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9809046A FR2781158B1 (fr) 1998-07-15 1998-07-15 Nouvelles proteines modifiees immunogenes non immunosuppressives, leur procede de preparation et leurs applications
PCT/FR1999/001423 WO2000003732A1 (fr) 1998-07-15 1999-06-15 Utilisation de proteines immunogenes immunosuppressives et/ou angiogeniques rendues inactives, procede de preparation et applications pharmaceutiques ou vaccinales

Publications (1)

Publication Number Publication Date
DE69940692D1 true DE69940692D1 (de) 2009-05-20

Family

ID=9528642

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69940692T Expired - Lifetime DE69940692D1 (de) 1998-07-15 1999-06-15 Verwendung von immunogenen immunsuppressiven und/oder angiogenen proteinen die inaktiviert sind, verfahren zur deren herstellung, und verwendungen als pharmazeutikum oder impfstoff

Country Status (8)

Country Link
US (2) US7022482B2 (de)
EP (1) EP1096953B1 (de)
AT (1) ATE427757T1 (de)
AU (1) AU4149699A (de)
DE (1) DE69940692D1 (de)
ES (1) ES2325008T3 (de)
FR (1) FR2781158B1 (de)
WO (1) WO2000003732A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050244434A1 (en) * 1999-08-12 2005-11-03 Cohen David I Tat-based tolerogen compositions and methods of making and using same
US20050226890A1 (en) * 1999-08-12 2005-10-13 Cohen David I Tat-based vaccine compositions and methods of making and using same
FR2802426B1 (fr) * 1999-12-15 2004-04-02 Neovacs Utilisation de proteines immunogenes immunosuppressives et/ou angiogeniques rendues inactives, pour la production d'iga secretoires
FR2812813B1 (fr) * 2000-08-09 2004-11-26 Neovacs Utilisation d'immunogenes pour traiter ou prevenir au sein des tumeurs malignes les dereglements immunitaires induits par des facteurs extracellulaires
FR2828404B1 (fr) * 2001-08-10 2005-07-15 Neovacs Superimmunogene composite a usage vaccinal bifonctionnel pour le traitement des maladies associees a un desordre tissulaire stromal
FR2844514B1 (fr) * 2002-09-16 2007-10-19 Neovacs Produit immunogene stable comprenant des heterocomplexes antigeniques, compositions les contenant et procede de preparation
KR20040094635A (ko) * 2003-05-02 2004-11-10 주식회사 엠디바이오알파 항종양 활성의 유도를 위한 종양 백신의 제조방법 및그것을 함유하고 있는 약제 조성물
US20050208482A1 (en) * 2004-03-16 2005-09-22 Cohen David I Tat-based immunomodulatory compositions and methods for their discovery and use
EP3539567A1 (de) 2007-07-02 2019-09-18 Etubics Corporation Verfahren und zusammensetzungen zur erzeugung eines adenovirusvektors zur verwendung mit mehreren impfungen
ES2432863T3 (es) 2009-03-23 2013-12-05 Pin Pharma, Inc. Tratamiento del cáncer con polipéptidos inmunoestimuladores derivados de Tat del VIH
EP2567972A1 (de) * 2011-09-12 2013-03-13 Adriacell S.p.A. Antikörper gegen das E7-Protein des Humanen Papillomvirus (HPV)
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
JP2016533352A (ja) 2013-10-04 2016-10-27 ピーアイエヌ ファーマ インコーポレイテッド 免疫刺激性ＨＩＶ Ｔａｔ誘導体ポリペプチドによる癌の治療
CN117244043B (zh) * 2023-11-02 2024-09-20 徐州医科大学附属医院 破伤风类毒素在治疗血管内皮细胞损伤中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986006414A1 (en) 1985-04-29 1986-11-06 Genetic Systems Corporation Synthetic antigens for the detection of aids-related disease
DE3907721A1 (de) * 1989-03-10 1990-09-20 Behringwerke Ag Immunogene regionen auf dem e7-protein des humanen papillomvierus typ 16
US5753233A (en) * 1990-05-10 1998-05-19 Behring Diagnostics Gmbh Seroreactive epitopes on proteins of human papilloma-virus (HPV) 18
FR2677654B1 (fr) 1991-06-17 1995-11-17 Pasteur Merieux Serums Vacc Composes a effet immunogene anti-cytokine, a effet immunogene anticytostatique ou a effet vaccinal anti-infection a hiv.
US5308612A (en) * 1992-08-12 1994-05-03 Blue Marble Research, Inc. Uses of polystyrenesulfonate and related compounds as inhibitors of transactivating transcription factor (TAT) and as therapeutics for HIV infection and AIDS
WO1995031999A1 (en) 1994-05-23 1995-11-30 Immunogiology Research Institute, Inc. Compositions of transactivating proteins of human immunodeficiency virus
AUPN015794A0 (en) * 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
PL322143A1 (en) 1995-03-08 1998-01-05 Neovacs Non-topxic immunogenes originating frommretroviral regulator protein, antibodies as such, method of preparing them and pharmaceutic compositions containing them
US5874089A (en) 1995-10-02 1999-02-23 Georgetown University School Of Medicine Protecting against canine oral papillomavirus (copy)
US6200575B1 (en) 1996-03-07 2001-03-13 Neovacs Non-toxic immunogens derived from a retroviral regulatory protein antibodies preparation process and pharmaceutical compositions comprising them
FR2773156B1 (fr) 1997-12-26 2000-03-31 Biovacs Inc Nouveaux immunogenes anti-retroviraux (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida
US8600831B2 (en) 2010-10-07 2013-12-03 Verizon Patent And Licensing Inc. Automated automobile maintenance using a centralized expert system

Also Published As

Publication number Publication date
ES2325008T3 (es) 2009-08-21
US7022482B2 (en) 2006-04-04
FR2781158A1 (fr) 2000-01-21
WO2000003732A1 (fr) 2000-01-27
US20040001852A1 (en) 2004-01-01
EP1096953B1 (de) 2009-04-08
US7504479B2 (en) 2009-03-17
AU4149699A (en) 2000-02-07
ATE427757T1 (de) 2009-04-15
EP1096953A1 (de) 2001-05-09
FR2781158B1 (fr) 2002-12-13
US20060153862A1 (en) 2006-07-13

Similar Documents

Publication Publication Date Title
DE69940692D1 (de) Verwendung von immunogenen immunsuppressiven und/oder angiogenen proteinen die inaktiviert sind, verfahren zur deren herstellung, und verwendungen als pharmazeutikum oder impfstoff
ATE61228T1 (de) Immunogener protein- oder peptidkomplex, verfahren zur herstellung dieses komplexes und seine verwendung als immunstimulans und als impfstoff.
PT91381A (pt) Processo para a preparacao microbiologica de albumina de soro humano e de outras proteinas heterologas a partir de levedura
DK0585943T3 (da) Opløselige ligander for CD40
ATE326479T1 (de) Varianten von antigenen des menschlichen papillomvirus
ATE482267T1 (de) Tierzellen und verfahren für die replikation von influenza viren
ATE404587T1 (de) Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
ATE354655T1 (de) Humane antikörper gegen ctla-4 und deren verwendungen
UA42089C2 (uk) Протигрипозна вакцина на основі поверхневого антигену, спосіб її виробництва
DE69309044D1 (de) Behandlung von asthma
DE69435331D1 (de) Herstellung von menschlichen papillomavirus HBV-11 Kapsidprotein L1 und Virus-ähnliche Partikeln
DE69929612D1 (de) Purifikation von viruspräparaten
UA93855C2 (ru) Вакцина, способствует росту, базирующейся ha нейтрализующем эпитопе
DE69522216D1 (de) Zielzellen-bindende chimäre Peptide
ATE171216T1 (de) Expression und reinigung von rekombinantem, löslichem gewebefaktor
DK289285D0 (da) Thymopentin analoge
ATE203413T1 (de) IMPFSTOFFE BESTEHEND AUS PROTEIN- ODER PEPTID- ßCOCHLEATENß UND DEREN VERWENDUNG ZUR IMMUNISIERUNG
WO2001026682A3 (en) Modified plant viruses and methods of use thereof
ATE205401T1 (de) Lokale behandlung von psoriasis unter verwendung neutralisierender antikörper gegen il-8
DE69023648D1 (de) Herstellung eines virus und reinigung von virenüberzugsproteinen zur impfstoffverwendung.
DE69109298D1 (de) Verfahren zur modifizierung von zell-, gewebe- oder wirts-tropismus eines mikroorganismus, so erhaltene rekombinante mikroorganismen sowie deren verwendung in medizin und tiermedizin.
DE69735439D1 (de) Mutanten von streptococcaltoxin c und verfahren zu deren anwendung
ATE346860T1 (de) Mutanten von streptococcaltoxinen und vefahren zu deren anwendung
PT93178A (pt) Agente proteico anticanceroso
ATE374246T1 (de) Polypeptidfragmente mit einem c-terminalen teil von katalase aus helicobacter

Legal Events

Date Code Title Description
8364 No opposition during term of opposition